| oxaliplatin / Generic mfg. |
MOSAIC, NCT00275210: - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer |
|
|
| Completed | 3 | 2246 | Europe, RoW | Oxaliplatin (SR96669) | Sanofi | Colonic Neoplasms | 04/03 | 04/03 | | |
NCT00061815: Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer |
|
|
| Completed | 3 | 102 | US | cetuximab, Erbitux™, oxaliplatin, Eloxatin®, leucovorin, Wellcovorin®, 5-fluorouracil, 5-FU | Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Cancer | 12/04 | 11/05 | | |
NO16966, NCT00069095: A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 2035 | US, Canada, Europe, RoW | Oxaliplatin 130 mg/m^2, Eloxatin, Capecitabine 1000 mg/m^2, Xeloda, Bevacizumab 7.5 mg/kg, Avastin, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Efudex, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg | Hoffmann-La Roche | Colorectal Cancer | 01/06 | 04/09 | | |
NCT00126256: Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 570 | Europe | 5-fluorouracil, leucovorin, irinotecan, oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris, Fondation Francaise de Cancerologie Digestive, Sanofi | Colorectal Cancer, Metastasis | 02/06 | 02/06 | | |
| Completed | 3 | 627 | US, Canada, Europe, RoW | 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda] | Hoffmann-La Roche | Colorectal Cancer | 08/06 | 08/06 | | |
NCT00077233: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum |
|
|
| Terminated | 3 | 238 | US | cetuximab, C225, 5-FU, 5-fluorouracil, irinotecan, CPT-11, leucovorin, calcium folinate, oxaliplatin, Eloxatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Bristol-Myers Squibb, Eli Lilly and Company | Colorectal Cancer | 12/06 | 06/10 | | |
|
|
NCT00056446: Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 855 | US, Canada, Europe, RoW | Vatalanib, PTK787/ZK 222584 | Novartis Pharmaceuticals, Bayer | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms | 01/07 | 01/07 | | |
|
NCT00115765: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study |
|
|
| Completed | 3 | 1053 | NA | Oxaliplatin Based Chemotherapy, FOLFOX 4, FOLFOX 5, Modified FOLFOX 6, FOLFOX 7, Oxaliplatin, Panitumumab, pmab, Vectibix, Irinotecan Based Chemotherapy, FOLFIRI, Douillard, Bevacizumab, Avastin | Amgen | Colorectal Cancer | 05/07 | 05/09 | | |
NCT00252564: Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 247 | US | Bevacizumab, Avastin, Oxaliplatin, Eloxatin, Leucovorin, Fluorouracil, 5FU, Cetuximab, Erbitux | US Oncology Research, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center, Prologue Research International | Metastatic Colorectal Cancer | 06/07 | 06/09 | | |
NCT00012389: Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | | US, Canada, Europe, RoW | irinotecan hydrochloride, oxaliplatin | Sanofi | Colorectal Cancer | | 10/08 | | |
NCT00349336: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 3 | 64 | Canada, RoW | bevacizumab [Avastin], XELOX, FOLFOX-4 | Hoffmann-La Roche | Colorectal Cancer | 11/08 | 11/08 | | |
NCT00786058: A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 |
|
|
| Approved for marketing | 3 | | Europe | OFF in experimental arm, Eloxatin, Calciumfolinat, 5-Fluorouracil | CONKO-Studiengruppe, Sanofi, medac GmbH, Amgen | Pancreatic Cancer | | | | |
NCT00208546: Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer |
|
|
| Completed | 3 | 750 | Europe | 21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Dutch Colorectal Cancer Group, Koningin Wilhelmina Fonds, Sanofi, Roche Pharma AG, Immunicon | Colorectal Cancer | 07/09 | 12/09 | | |
|
|
|
|
NCT00305188 / 2005-002570-30: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. |
|
|
| Completed | 3 | 879 | US, Canada, Europe, RoW | Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, 5-FU, Leucovorin, LV | Sanofi | Metastases, Colorectal Neoplasms, Colorectal Carcinoma | 10/09 | 10/09 | | |
| Completed | 3 | 249 | Europe | erlotinib (Tarceva), bevacizumab (Avastin) | Lund University Hospital, Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
|
|
|
|
|
XENON, NCT00603577 / 2007-000945-36: Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens |
|
|
| Terminated | 3 | 102 | US, Canada, Europe | Placebo, Xaliproden | Sanofi | Colorectal Neoplasms | 11/09 | 11/09 | | |
| Completed | 3 | 1254 | Europe, RoW | Cediranib, AZD2171, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Other Names:, 5-FU, Drug: Leucovorin (in FOLFOX), intravenous infusion, Drug: Oxaliplatin (in FOLFOX), Eloxatin®, XELOX (Capecitabine and Oxaliplatin), Xeloda® + Eloxatin®, Cediranib Placebo | AstraZeneca | Metastatic Colorectal Cancer | 03/10 | 08/16 | | |
|
|
|
|
NCT00471965: Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients |
|
|
| Completed | 3 | 371 | RoW | Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin | Sanofi | Carcinoma, Hepatocellular | 03/10 | 03/10 | | |
AVANT, NCT00112918: Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer |
|
|
| Completed | 3 | 3451 | US | Bevacizumab, Capecitabine, Xeloda®, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin | Hoffmann-La Roche, National Cancer Institute (NCI) | Colorectal Cancer | 06/10 | 06/12 | | |
|
NCT00062426: Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | | US | bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | | 02/11 | | |
VELOUR, NCT00561470 / 2007-000820-42: Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen |
|
|
| Completed | 3 | 1226 | US, Europe, RoW | Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Sanofi, Regeneron Pharmaceuticals, NSABP Foundation Inc | Colorectal Neoplasms, Neoplasm Metastasis | 02/11 | 06/12 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00440310 / 2006-004214-41: Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases |
|
|
| Completed | 3 | 483 | Europe, RoW | Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes, FOLFOX4 regimen, FOLFIRI regimen | Light Sciences Oncology | Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local | 05/11 | 10/11 | | |
NCT00623805: A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 123 | RoW | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Hoffmann-La Roche | Colorectal Cancer | 05/12 | 05/12 | | |
|
NCT00335595 / 2005-003325-67: Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients |
|
|
| Completed | 3 | 480 | Europe | XELOXA, XELOXA-A | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi, Roche Pharma AG | Colorectal Cancer | 06/12 | 06/12 | | |
|
| Completed | 3 | 847 | US, Canada, Europe, RoW | Pegfilgrastim, Neulasta®, Placebo, Bevacizumab, Avastin®, Standard Chemotherapy | Amgen | Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer | 09/12 | 01/15 | | |
|
|
| Completed | 3 | 1035 | RoW | Capecitabine, Oxaliplatin | Sanofi, Hoffmann-La Roche | Stomach Neoplasms | 11/12 | 11/12 | | |
NCT02560974: A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer |
|
|
| Completed | 3 | 1035 | RoW | Capecitabine, Xeloda, Oxaliplatin | Hoffmann-La Roche | Gastric Cancer | 11/12 | 11/12 | | |
| Completed | 3 | 200 | Canada | Glutamine, Calcium and Magnesium | Sanofi | Colorectal Neoplasms | 03/13 | 03/13 | | |
| Completed | 3 | 820 | Europe, RoW | Chemotherapy, Bevacizumab, Avastin | Hoffmann-La Roche | Colorectal Cancer | 05/13 | 05/13 | | |
|
|
|
|
|
|
|
|
| Terminated | 3 | 79 | Europe | oxaliplatin+capecitabine, Oxaliplatin+capecitabine+bevacizumab | Dutch Colorectal Cancer Group, Sanofi, Roche Pharma AG | Colorectal Cancer, Liver Metastases | 08/13 | 08/13 | | |
|
NCT01121848: Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer |
|
|
| Completed | 3 | 108 | Canada | Leucovorin, OXALIPLATIN, 5-Fluorouracil | Sanofi | Pancreatic Neoplasms | 10/13 | 10/13 | | |
SECOX, NCT01245582: Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients |
|
|
| Withdrawn | 3 | 0 | RoW | oxaliplatin (SR96669), capecitabine, sorafenib | Sanofi | Hepatic Neoplasm Malignant | 02/14 | 08/15 | | |
NCT02060669: Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer |
|
|
| Terminated | 3 | 10 | RoW | Xeloda | Samsung Medical Center, Roche Pharma AG | Metastatic Colorectal Cancer | 05/14 | 09/14 | | |
AFLAME, NCT01661270: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy |
|
|
| Completed | 3 | 332 | Japan, RoW | Aflibercept, AVE0005, Zaltrap, Placebo | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 10/14 | 07/15 | | |
| Completed | 3 | 853 | Europe | 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab | AIO-Studien-gGmbH, Roche Pharma AG | Colorectal Neoplasms | 12/14 | 08/15 | | |
|
|
|
NCT01338558: A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab |
|
|
| Withdrawn | 3 | 0 | Europe | bevacizumab [Avastin], cetuximab, mFOLFOX6 | Hoffmann-La Roche | Colorectal Cancer | 05/15 | 05/15 | | |
| Completed | 3 | 175 | Europe | AFLIBERCEPT, AVE0005, Irinotecan, Fluorouracil, Leucovorin | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 06/15 | 06/15 | | |
|
|
NCT01662869 / 2012-001402-23: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer |
|
|
| Completed | 3 | 564 | US, Canada, Europe, RoW | 5-Fluoruracil, Folinic acid, Onartuzumab, MetMAb, RO5490258, PRO143966, Oxaliplatin, Placebo | Hoffmann-La Roche, Genentech, Inc. | Gastric Cancer | 12/15 | 12/15 | | |
|
|
|
NCT01571284 / 2011-005724-17: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen |
|
|
| Completed | 3 | 781 | US, Canada, Europe, RoW | AFLIBERCEPT AVE0005, FOLFIRI | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 01/17 | 01/17 | | |
|
|
|
|
|
|
VISNU-1, NCT01640405 / 2012-000846-37: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells |
|
|
| Completed | 3 | 350 | Europe | modified FOLFOX6 + bevacizumab, FOLFOXIRI + Bevacizumab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Metastatic Colorectal Cancer | 11/18 | 11/18 | | |
NCT01824459: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients |
|
|
| Completed | 3 | 576 | RoW | S-1, Oxaliplatin, Cisplatin | Sun Yat-sen University, Taiho Pharmaceutical Co., Ltd. | Gastric Cancer | 12/18 | 12/18 | | |
FAST, NCT00735241: FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma |
|
|
| Withdrawn | 2/3 | 0 | US | SIR-Spheres microspheres, FOLFOX6 cycles 1-3, Eloxatin, Folinic acid, 5-FU, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards, Avastin | Sirtex Medical | Colorectal Carcinoma, Liver Metastases | 03/09 | 03/09 | | |
| Completed | 2/3 | 1814 | US, Canada, Europe, RoW | Cediranib, RECENTIN™, AZD2171, Bevacizumab, Avastin®, 5-fluorouracil ( in FOLFOX), 5-FU, Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX), Eloxatin® | AstraZeneca | Colorectal Cancer | 11/09 | 08/15 | | |
|
|
|
|
|
NCT01550055: Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer |
|
|
| Completed | 2/3 | 512 | NA | CMAB009 plus Irinotecan, YiMaiLin for irinotecan, Irinotecan-only and sequential-CMAB009 | Shanghai Zhangjiang Biotechnology Limited Company, Shanghai Biomabs Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 12/12 | 07/15 | | |
BOS3, NCT01646554: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases |
|
|
| Withdrawn | 2/3 | 0 | NA | Modified FOLFOX6, 5-FU, folinic acid, oxaliplatin, Aflibercept, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Sanofi | Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer | 12/15 | 12/16 | | |
